Psychedelic-assisted pharmacotherapy: clinical applications and regulatory considerations.
Level 5 - mechanism / opinion, no new human data
Narrative review synthesizing existing trial literature and regulatory documents without systematic review methodology.
PubMed 41944071 · doi:10.1080/14656566.2026.2654682
What was done
This narrative review synthesized evidence from phase II-III clinical trials, regulatory agency documents, and international drug policy frameworks regarding psychedelic-assisted therapies across major depressive disorder, treatment-resistant depression, PTSD, anxiety disorders, and substance use disorders. It examined ketamine/esketamine, MDMA, psilocybin, LSD, DMT/5-MeO-DMT, and ibogaine with a focus on regulatory pathways, scheduling, access mechanisms, and approval trajectories in the United States, the European Union, and select international jurisdictions.
What was found
The abstract reports no numerical results or sample sizes. It qualitatively describes late-stage clinical trial evidence indicating rapid and sustained effects on mood, cognition, and behavior in treatment-resistant conditions. It also concludes that these therapies require specialist-delivered, psychotherapy-integrated models under specific regulatory safeguards rather than traditional prescription models, while noting unresolved challenges in long-term safety, scalability, workforce training, equity, and medico-legal accountability.
Why it matters
This review highlights the specific regulatory, operational, and clinical delivery challenges that must be solved before psychedelic-assisted psychiatric treatments can transition from clinical trials to standard healthcare delivery.
Limits
The abstract contains no quantitative metrics, effect estimates, or study counts. Because it is a narrative review rather than a systematic review, it lacks formal methodology for study selection, risk-of-bias evaluation, or pooled statistical analysis.
Cited by
- supports Ketamine is classified as a DEA Schedule III drug in the United States, while psilocybin and MDMA are Schedule I.